PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents changing 6.22% while AXSM's remains stable. Warren Buffett would analyze the strategic implications of this divergence.
-100.00%
Both AXSM and the company show zero Short-Term Investments Growth.
6.22%
Higher Cash + Short-Term Investments Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
13.80%
Higher Total Current Assets Growth compared to AXSM's zero value, indicating better performance.
2.11%
Higher PP&E (Net) Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Higher Total Non-Current Assets Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Higher Total Assets Growth compared to AXSM's zero value, indicating better performance.
62.36%
Higher Accounts Payable Growth compared to AXSM's zero value, indicating worse performance.
-40.14%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
133.46%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
184.58%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
173.41%
Higher Total Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Higher Total Liabilities Growth compared to AXSM's zero value, indicating worse performance.
4.06%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
-25.11%
Both AXSM and the company show zero Retained Earnings Growth.
-90.06%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AXSM's zero value, indicating worse performance.
-763.59%
Both AXSM and the company show zero Total Stockholders' Equity Growth.
13.78%
Higher Liabilities + Equity Growth compared to AXSM's zero value, indicating better performance.
-100.00%
Both AXSM and the company show zero Total Investments Growth.
-40.14%
Higher Total Debt Growth compared to AXSM's zero value, indicating worse performance.
-7.59%
Higher Net Debt Growth compared to AXSM's zero value, indicating worse performance.